Amino-Carbonyl Reactions in the Aging Human Lens
Amino-Carbonyl Reactions in the Aging Human Lens
批准号:
7385908
负责人:
VINCENT M MONNIER
金额:
$36.75万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-08-01 至 2011-02-28
关键词:
AcuteAddressAgeAgingAging-Related ProcessAnimal ModelAntioxidantsArginineAscorbic AcidBackBiochemicalBiologicalBreedingCataractCell NucleusChemicalsChronicClassificationConditionCrossbreedingCrystallinsCysteineCysteine SynthaseDehydroascorbic AcidDocosahexaenoic AcidsEnd PointEnzymesEpithelial CellsExposure toFluorineFundingFutureGeneticGlutathioneHomeostasisHumanHybridsImpairmentIn VitroInterventionIntervention StudiesKnock-outKnockout MiceLabelLigaseLong-Term EffectsLongitudinal StudiesLysineMaillard ReactionModelingModificationMolecularMolecular ChaperonesMusNMR SpectroscopyNatural regenerationNumbersOrnithineOutcomeOxidantsOxidation-ReductionPigmentation physiologic functionProductionPropertyProtein OverexpressionProteinsReactionRecyclingResearchRodentSodiumStressStructureTestingTimeToxic effectTransgenesTransgenic AnimalsTransgenic MiceTransgenic Organismsascorbatebasecofactordiabeticdisulfide bondgenetic manipulationglycationin vivolensmetabolomicsmouse modelnoveloxidationprogramsprotein crosslinkresearch studystressorsugartool developmentuptakevesperlysine A
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This research program addresses the hypothesis that extensive damage to lens crystallins by amino-carbonyl reactions
between reducing sugars, ascorbic acid and proteins (so-called Maillard reaction) contributes to the aging of the human
lens. Our key hypothesis is that the accumulation of these glycation products predisposes the lens toward cataractogenesis,
and that much of the reaction is catalyzed by ascorbic acid oxidation products. Toward this hypothesis progress several
breakthroughs have been achieved in the previous funding period. First, the structure of the fluorophore LM-1 was
identified as Vesperlysine A, an ascorbate catalyzed protein crosslink that is specifically increased in diabetic human
lenses. Second, we discovered carboxymethyl-lysine, a major ascorbylation product, bindsredox active Cu 2+ in the human
lens. Third, we have pioneered a novel "metabolomics" approach based on fluorine-labeled ascorbic acid (F-ASA) and
high resolution19F-NMR spectroscopy and found that oxidatively stressed lens epithelial cells and cataracts accumulate
F-ASA degradation products. Fourth, we discovered, cloned and elucidated the catalytic mechanism of deglycating
enzymes for future use in transgenic animal models of excessive glycation. Finally and most recently, we discovered
evidence of extensive glycation-catalyzed conversion of arginine into ornithine in the aging human lens.
In the coming years we propose an entirely new and, we believe, highly promising approach to the problem of
lenticular aging by ascorbylation and glycation through the creation of three transgenic/conditionalknockout models of
accelerated damage to the lens. Based on the discovery that rodent lenses are deficient in ascorbic acid uptake, we propose
to first create a mouse model of the human lens by overexpressing the human Vitamin C Transporter 2 (hSVCT2) in the
lens. The impact of this transgene on lenticular homoestasis, protein pigmentation, fragmentation and crosslinkingwill be
studied. This humanized hSVCT+/+ mouse will be then be crossbred with a mouse deficient in glutathionesynthesis
obtained by conditionally knocking out y-glutamyl cysteine ligase (yGclc)from the lens. The impact of the knockouton
lens crystallin changes with be similarly studied. The homozygous hSVCT^/yGcIc"'" hybrid mouse lens is expected to
accumulate substantial levels of reactive ascorbylation products due to impairment of ascorbic acid recycling. The
approach taken will allow us to study separately the impact of multipleforms of protein damage, i.e. ascorbylation,
glycation and oxidation on lens chaperone and other properties. With the help of these genetic manipulations, it is hoped
that the 70-yr long aging process of the human lens can be condensed into 24 mos. This mouse model is expected to
become a potent tool for the development of novel genetic and pharmacological interventions against lenticular aging.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression
-
批准号:10164795
-
项目类别:
-
资助金额:$65.86万
-
财政年份:2019
-
负责人:VINCENT M MONNIER
-
依托单位:
10th International Symposium on the Maillard Reaction
-
批准号:7751127
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2009
-
负责人:VINCENT M MONNIER
-
依托单位:
9th International Symposium on the Maillard Reaction
-
批准号:7407292
-
项目类别:
-
资助金额:$1.65万
-
财政年份:2007
-
负责人:VINCENT M MONNIER
-
依托单位:
Core--Animal facility
-
批准号:6659261
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2002
-
负责人:VINCENT M MONNIER
-
依托单位:
Oxidant stress & ascorbic acid processing in diabetes
-
批准号:6659258
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2002
-
负责人:VINCENT M MONNIER
-
依托单位:
Oxidant stress & ascorbic acid processing in diabetes
-
批准号:6504045
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2001
-
负责人:VINCENT M MONNIER
-
依托单位:
Core--Animal facility
-
批准号:6504048
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2001
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6795825
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
CORE--ANIMAL
-
批准号:6359556
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6452358
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
Core--Animal facility
-
批准号:6360796
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6533891
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6200051
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6372531
-
项目类别:
-
资助金额:$28.24万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
Oxidant stress & ascorbic acid processing in diabetes
-
批准号:6360791
-
项目类别:
-
资助金额:$9.46万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
COLLAGEN CROSSLINKING BY THE MAILLARD REACTIOIN IN AGING
-
批准号:6648499
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2000
-
负责人:VINCENT M MONNIER
-
依托单位:
CORE--ANIMAL
-
批准号:6218776
-
项目类别:
-
资助金额:$0.23万
-
财政年份:1999
-
负责人:VINCENT M MONNIER
-
依托单位:
CORE--ANIMAL
-
批准号:6098820
-
项目类别:
-
资助金额:$0.23万
-
财政年份:1999
-
负责人:VINCENT M MONNIER
-
依托单位:
CORE--ANIMAL
-
批准号:6267778
-
项目类别:
-
资助金额:$9.55万
-
财政年份:1998
-
负责人:VINCENT M MONNIER
-
依托单位:
GLYOXAL & GLYCOLALDEHYDE PROTEIN MODIFICATION, MAILLARD REACTION INTERMEDIATE
-
批准号:6248417
-
项目类别:
-
资助金额:$0.46万
-
财政年份:1997
-
负责人:VINCENT M MONNIER
-
依托单位:
海外基金